Baldness breakthrough? own cells injected into scalp to regrow hair

NCT ID NCT07618195

Recruiting now Disease control Sponsor: Epibiotech Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new treatment called EPI-001 for androgenetic alopecia (common baldness). EPI-001 is made from a patient's own scalp cells and injected into the scalp. The trial has two parts: first, finding the safest dose in a small group, then comparing the best dose to a placebo in 42 people. Researchers will check for side effects and measure hair growth over up to 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EPI-001 (a cell-based injection made from the patient's own scalp cells)
What this could lead to: If it works, this could point toward a new treatment for male and female pattern baldness that uses a person's own cells to regrow hair.
What could go wrong: This is an early-phase trial with only 42 people, so it is too soon to know if it works. The treatment involves injections and may cause side effects like pain or swelling.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANDROGENETIC ALOPECIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANDROGENETIC ALOPECIA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Chung-Ang University Hospital
RECRUITING

Seoul, Seoul, 06973, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.